Kyung Dong Pharmaceutical Co. Ltd (011040) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Kyung Dong Pharmaceutical Co. Ltd KRW 6,092, price KRW 5,020, upside +21.4%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kyung Dong Pharmaceutical Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 4,720 KRW – 12,867 KRW · fair‑value band 4,498 KRW – 7,706 KRW · the 5,020 KRW price screens below the 6,092 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Kyung Dong Pharmaceutical Co. in your weekly email
Every Wednesday you see whether Kyung Dong Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea.
Show more
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, antihistamine, CNS, antiobesity, neuropathic, osteoporosis, respiratory, allergy, and arthrifuge categories. The company also provides OTC medicines for pain/inflammation, cardiovascular, hepatic protectors, respiratory, gastrointestinal, calcium agent, antihistamine, antifungal, antibiotic, anti-inflammatory enzyme, dermatologic, antiviral, and contraceptive categories; and APIs and health functional foods, as well as quasi drugs. The company was formerly known as Yuil Trading Company and changed its name to Kyung Dong Pharmaceutical Co., Ltd. in February 1976. Kyung Dong Pharmaceutical Co., Ltd. was founded in 1975 and is headquartered in Seoul, South Korea.
Stock analysis
Kyung Dong Pharmaceutical Co. Ltd (011040) currently trades at 5,020 KRW, while our model-based Fair Value estimate is 6,092 KRW, implying the stock looks roughly 17.6% undervalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 6,506 KRW per share, and 8 of the 12 models we run sit above the 5,020 KRW price.
Bear case: the Earnings-Based group reads lowest at 2,013 KRW, and 4 of the 12 models stay below the price. Evidence for this calculation is medium.
Scenario range: 4,498 KRW (bear) to 7,706 KRW (bull), the price of 5,020 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Kyung Dong Pharmaceutical Co. Ltd reported revenue of 196B KRW in FY2025 versus 178B KRW in FY2021, a compound +2.5%/yr. Reported net income was 8.5B KRW in FY2025, compounding −9.4%/yr from FY2021.
Key figures
Market cap 146B KRW (≈ $107M) · P/S ratio 0.80 · Dividend yield 5.1% · Net margin 4.3% · Return on equity 271% · Return on assets (EBIT) 0.5% · Operating margin 6.1% · Revenue (TTM) 182B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 17% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at 21%, 011040 screens cheaper than that median.
Fair Value models
Bear 4,498 KRWFair Value 6,092 KRWBull 7,706 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Start year 2020 (pandemic). Over 10 years: +2.6% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−2.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.4%
Dividend (yield on the price)5.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−7% vs −8%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 4%
Compare Kyung Dong Pharmaceutical Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 55 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Kyung Dong Pharmaceutical Co. Ltd (011040) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6,092 KRW versus a price of 5,020 KRW, about +21% upside (undervalued).
What is the fair value of 011040?
Our model-based fair value for Kyung Dong Pharmaceutical Co. Ltd is 6,092 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,020 KRW.
What is the quality score of 011040?
Kyung Dong Pharmaceutical Co. Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kyung Dong Pharmaceutical Co. Ltd (011040)?
Our model-based price target is the fair value of 6,092 KRW (as of Sep 24, 2026) from 12 valuation models. Cautious scenario 4,498 KRW, optimistic scenario 7,706 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Kyung Dong Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 6,092 KRW, about +21% upside versus a price of 5,020 KRW (undervalued). Cautious scenario 4,498 KRW, optimistic scenario 7,706 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kyung Dong Pharmaceutical Co. Ltd (011040)?
Kyung Dong Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 182B KRW (latest available figure, as of Sep 24, 2026).
Does Kyung Dong Pharmaceutical Co. Ltd pay a dividend?
Kyung Dong Pharmaceutical Co. Ltd currently shows a dividend yield of about 5.14% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Kyung Dong Pharmaceutical Co. Ltd (011040)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kyung Dong Pharmaceutical Co. Ltd it is 6,092 KRW per share (as of Sep 24, 2026), against a price of 5,020 KRW. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Kyung Dong Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 011040 trades below its calculated fair value: price 5,020 KRW, fair value 6,092 KRW, a gap of about +21% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 011040?
No. The price is what the market pays today (5,020 KRW); the fair value is what the company's own numbers justify (6,092 KRW). For Kyung Dong Pharmaceutical Co. Ltd the two are 1,072 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kyung Dong Pharmaceutical Co. Ltd worth?
The market values Kyung Dong Pharmaceutical Co. Ltd at about 146B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,020 KRW; our models calculate a fair value of 6,092 KRW per share.
What do the bullish and bearish scenarios say about 011040?
Our models span a range for Kyung Dong Pharmaceutical Co. Ltd: cautious scenario 4,498 KRW, base 6,092 KRW, optimistic 7,706 KRW per share (as of Sep 24, 2026, price 5,020 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kyung Dong Pharmaceutical Co. Ltd (011040)?
Balance-sheet figures for Kyung Dong Pharmaceutical Co. Ltd (as of Sep 24, 2026): return on equity 270.9%, debt of 0.07 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 011040 from its 52-week high?
Kyung Dong Pharmaceutical Co. Ltd trades at 5,020 KRW, about 17% below its 52-week high of 6,030 KRW and 6% above the low of 4,720 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 6,092 KRW is for.
Which stocks are comparable to Kyung Dong Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kyung Dong Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 5,020 KRW, calculated fair value 6,092 KRW (+21%), Quality Score 58/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 011040 calculated?
We run Kyung Dong Pharmaceutical Co. Ltd through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6,092 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Kyung Dong Pharmaceutical Co. Ltd currently trades 21 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The closing price on Sep 23, 2026 was 5,020 KRW. Our model-based fair value is 6,092 KRW, about +21% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kyung Dong Pharmaceutical Co. Ltd right now?
Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Kyung Dong Pharmaceutical Co. Ltd
How large is the market capitalisation of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The market capitalisation of Kyung Dong Pharmaceutical Co. Ltd is 146B KRW (≈ $107M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The price-to-sales ratio of Kyung Dong Pharmaceutical Co. Ltd is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The dividend yield of Kyung Dong Pharmaceutical Co. Ltd is 5.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The net margin of Kyung Dong Pharmaceutical Co. Ltd is 4.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The return on equity (ROE) of Kyung Dong Pharmaceutical Co. Ltd is 271% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kyung Dong Pharmaceutical Co. Ltd (011040)?
On an EBIT basis the return on assets of Kyung Dong Pharmaceutical Co. Ltd is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kyung Dong Pharmaceutical Co. Ltd (011040)?
The operating margin of Kyung Dong Pharmaceutical Co. Ltd is 6.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kyung Dong Pharmaceutical Co. Ltd (011040)?
Revenue at Kyung Dong Pharmaceutical Co. Ltd is growing −3.8% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kyung Dong Pharmaceutical Co. Ltd (011040)?
Earnings per share at Kyung Dong Pharmaceutical Co. Ltd are growing −51.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kyung Dong Pharmaceutical Co. Ltd (011040) generate?
The free cash flow of Kyung Dong Pharmaceutical Co. Ltd is −3.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kyung Dong Pharmaceutical Co. Ltd (011040) carry?
The net debt of Kyung Dong Pharmaceutical Co. Ltd is 13.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kyung Dong Pharmaceutical Co. Ltd in the live analysis
One click puts Kyung Dong Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
